Companies / Inhibikase Therapeutics, Inc. / Activity
Activity — Inhibikase Therapeutics, Inc.
7 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 21, 2026 | Cabell Christopher Executive | Other | Common Stock | $0 | -338K -33.33% | 676,564 0.48% of shares | low |
| Feb 21, 2026 | Aurentz Vincent Director | Other | Common Stock | $0 | -255K -33.33% | 510,596 0.37% of shares | low |
| Feb 21, 2026 | Munshi Amit Director | Other | Common Stock | $0 | -19K -33.33% | 38,176 0.03% of shares | low |
| Jun 26, 2026 | Berman Dennis N Director | Grant | Stock Option (Right to Buy) | — | +155K | 155,000 0.11% of shares | low |
| Jan 5, 2026 | Cabell Christopher Executive | Grant | Stock Option (Right to Buy) | — | +900K | 900,117 0.65% of shares | low |
| Jan 5, 2026 | Iwicki Mark T CEO | Grant | Stock Option (Right to Buy) | — | +5.0M | 4,982,706 3.57% of shares | low |
| Jan 5, 2026 | McIntyre David Executive | Grant | Stock Option (Right to Buy) | — | +986K | 986,319 0.71% of shares | low |